The Korea Biomedical Review reports that, on 16 April 2024, Merck Sharp & Dohme (MSD) announced that it obtained approval in Korea for an expanded indication for its Keytruda® (pembrolizumab) as a combination therapy with chemoradiotherapy for treating FIGO (International Federation of Genecology and Obstetrics) 2014 stage III-IVA cervical cancer.
The same indication was approved in the US by the FDA in January 2024. This followed the FDA approval in October 2021 for Keytruda® plus chemotherapy, with or without bevacizumab, as a treatment for patients with persistent, recurrent or metastatic cervical cancer whose tumours express PD-L1.